The prevalence and diagnostic utility of bronchodilator responsiveness (BDR) in a real-life setting is unclear. Objective: To explore this uncertainty
The COPD Foundation is kicking off its 20th anniversary year with exciting news! Bronchiectasis and NTM 360, a division of the COPD Foundation, is thrilled to announce its journey to establish a Bronchiectasis and NTM Care Center Network.
We explore this concept and look at atopic dermatitis, chronic rhinosinusitis with nasal polyps, etc., as treatable traits of asthma and how these can be managed.
Since 2001 the GOLD publishes and updates every year a document that recommends how to best diagnose and manage COPD. The GOLD 2024 document has just been released and is available for free download in the GOLD website.
TT guided asthma management for 10 weeks reduced T2 inflammation.
Join the international educational symposium on Chronic Obstructive Pulmonary Disease (COPD). 2023 marks the 8th Annual GOLD International COPD Conference.
COPD is a common, preventable, and treatable disease, but extensive under-diagnosis and misdiagnosis leads to patients receiving no treatment or incorrect treatment.
The Global Burden of Disease Study 2017 identified that a country’s sociodemographic index was a key factor affecting mortality and loss of health from respiratory diseases.
1 year after an acute COVID-19 episode, patients with either lung sequelae or long COVID show a stronger SARS-CoV-2-specific T-cell response than fully recovered individuals, suggesting persistent cell stimulation by residual viral reservoirs
Chief Editor James Chalmers interviews Alvar Agusti (Hospital Clinic, Barcelona, Spain)about the new Global Initiative for Chronic Obstructive Lung Disease (GOLD) report. Listen it here.
